• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishDashboard
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI employees
    Legal
    Terms of usePrivacy policyCookie policy

    FDA Approval for SIMLANDI issued to ALVOTECH USA INC

    8/27/24 5:06:08 PM ET
    $ALVO
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care
    Get the next $ALVO alert in real time by email
    Biologic License Application (BLA): 761299
    Company: ALVOTECH USA INC
    • Email
    • Medication Guide

    Products on BLA 761299

    Drug Name Active Ingredients Strength Dosage Form/Route Marketing Status TE Code RLD RS
    SIMLANDI ADALIMUMAB-RYVK 40MG/0.4ML INJECTABLE;INJECTION Prescription None No No

    Approval Date(s) and History, Letters, Labels, Reviews for BLA 761299

    Original Approvals or Tentative Approvals
    Action Date Submission Action Type Submission Classification Review Priority; Orphan Status Letters, Reviews, Labels, Patient Package Insert Notes Url
    02/23/2024 ORIG-1 Approval N/A Label (PDF)
    Letter (PDF)
    Review
    https://www.accessdata.fda.gov/drugsatfda_docs/label/2024/761299s000lbl.pdf https://www.accessdata.fda.gov/drugsatfda_docs/appletter/2024/761299Orig1s000ltr.pdf https://www.accessdata.fda.gov/drugsatfda_docs/nda/2024/761299Orig1s000TOC.cfm
    Supplements
    Action Date Submission Supplement Categories or Approval Type Letters, Reviews, Labels, Patient Package Insert Note Url
    06/26/2024 SUPPL-7 Supplement Letter (PDF)

    Label is not available on this site.

    https://www.accessdata.fda.gov/drugsatfda_docs/appletter/2024/761299Orig1s007correctedltr.pdf
    08/26/2024 SUPPL-6 Supplement Letter (PDF)

    Label is not available on this site.

    https://www.accessdata.fda.gov/drugsatfda_docs/appletter/2024/761299Orig1s003, s006ltr.pdf
    08/26/2024 SUPPL-3 Supplement Letter (PDF)

    Label is not available on this site.

    https://www.accessdata.fda.gov/drugsatfda_docs/appletter/2024/761299Orig1s003, s006ltr.pdf
    05/31/2024 SUPPL-1 Supplement Label (PDF)
    Letter (PDF)
    https://www.accessdata.fda.gov/drugsatfda_docs/label/2024/761299s001lbl.pdf https://www.accessdata.fda.gov/drugsatfda_docs/appletter/2024/761299Orig1s001ltr.pdf

    Labels for BLA 761299

    Action Date Submission Supplement Categories or Approval Type Letters, Reviews, Labels,
    Patient Package Insert
    Note Url
    05/31/2024 SUPPL-1 Labeling-Package Insert Label (PDF) https://www.accessdata.fda.gov/drugsatfda_docs/label/2024/761299s001lbl.pdf
    02/23/2024 ORIG-1 Approval Label (PDF) https://www.accessdata.fda.gov/drugsatfda_docs/label/2024/761299s000lbl.pdf
    Get the next $ALVO alert in real time by email

    Chat with this insight

    Save time and jump to the most important pieces.

    Recent Analyst Ratings for
    $ALVO

    DatePrice TargetRatingAnalyst
    2/14/2025$18.00Buy
    UBS
    1/29/2024$10.00 → $17.00Equal Weight → Overweight
    Barclays
    10/20/2023$5.00 → $10.00Sell → Neutral
    Citigroup
    9/21/2023$10.00Equal Weight
    Barclays
    9/7/2022$10.00Equal-Weight
    Morgan Stanley
    9/6/2022$12.00 → $5.00Buy → Sell
    Citigroup
    More analyst ratings